Prosthetic Heart Valves Are Critical Component of the Treatment of Patients with Vulvular Heart Disease
Prosthetic Heart Valves |
Prosthetic Heart Valves (SHVs) are designed to replace the
damaged valves of the human heart. They are a critical component of the
treatment of patients with valvular heart disease. A variety of mechanical and
bioprosthetic heart valves are available for aortic and mitral valve replacement.
They have been developed to improve hemodynamics, avoid anticoagulation
requirements, and minimize biological response to the prosthesis.
Mechanical valves are composed of a strutted or disc-like
structure with an occluder in the center and an opening orifice at either end. Prosthetic
Heart Valves shape
and the degree of strut movement can determine the flow resistance, the area of
turbulent shear stress, and the overall efficacy of the prosthesis. These
designs have also been developed to minimize acoustic shadowing.
Tissue-derived heart valves are made from animal or
non-animal tissue sources. They can be either valvular or non-valvular, and are
typically fixed in glutaraldehyde to reduce the risk of immunogenicity. In this
process, the antigens are removed and cross-linked so that they are not recognized
by the body. However, the resulting prostheses have been reported to suffer
from structural valve degeneration. Hence, they are often subject to
reintervention for symptomatic dysfunction.
The surgical bioprosthetic valve is an increasingly popular
alternative to aortic and mitral prostheses. Prosthetic Heart Valves offer the advantage of avoiding
anticoagulation, however, require ongoing monitoring of internationalized normalized
ratios to ensure patient compliance. Consequently, they are associated with the
risk of bleeding and thromboembolism.
Several studies have been conducted to evaluate the
performance of bioprosthetic leaflets in different physiological conditions.
The main objective is to understand the stress and strain distribution of the
leaflets during a cardiac cycle. Some of these studies use a linear elastic
orthotropic material model, while others rely on a shell model. Among the
latter, Fung’s constitutive model has been widely used to simulate the stress
response of bioprosthetic valve leaflets. In March 2022, the U.S. Food and Drug
Administration (FDA) granted approval to Edwards Lifesciences for the MITRIS
RESILIA valve.
Comments
Post a Comment